Rybrevant (amivantamab-vmjw)

RybrevantTM (amivantamab-vmjw) is a drug used to treat adults with non-small cell lung cancer (NSCLC) that:1

  • Has spread to other parts of the body (metastatic) or is locally advanced (cancer has progressed within the lung region), and
  • Has epidermal growth factor receptor (EGFR) exon 20 insertion mutations, and
  • Whose disease has worsened while on or after receiving platinum-based chemotherapy

Ryrevant is the first targeted treatment option for people with NSCLC who have EGFR exon 20 insertion genetic mutations.1

The Guardant360 CDx is a companion diagnostic used with Rybrevant. A companion diagnostic can help determine which people are right for therapy based on tumor characteristics.1,2

The U.S. Food and Drug Administration (FDA) granted Rybrevant:1

  • Priority Review – The FDA can grant Priority Review when a new drug seems promising and may help treat a disease compared to existing treatments. Priority Review means the FDA will typically review the drug and decide whether to grant approval within 6 months. It may be applied in cases where a given drug seems to work better or is safer than current treatments.
  • Breakthrough Therapy designation – This helps certain drugs get reviewed and developed faster. Drugs may qualify if they treat a serious condition and initial evidence shows a significant improvement over currently available treatments.

According to the American Cancer Society, lung cancer is the most common type of cancer. It is the leading cause of death from cancer worldwide. NSCLC makes up about 80 to 85 percent of all lung cancers. About 2 or 3 percent of people with NSCLC have mutations called epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These mutations allow the cancer to grow and spread.1

What are the ingredients in Rybrevant?

The active ingredient in Rybrevant is amivantamab-vmjw.1

How does Rybrevant work?

Rybrevant is a monoclonal antibody. A monoclonal antibody is a specific immune system protein that is made in a lab. Rybrevant targets 2 proteins that help cancer grow: EGFR and MET. Rybrevant binds to these proteins, which can help slow the growth of cancer cells and cause them to die.1-4

What are the possible side effects of Rybrevant?

The most common side effects of Rybrevant include:1,4

  • Rash
  • Infected skin around the nail
  • Muscle and joint pain
  • Shortness of breath
  • Nausea, vomiting
  • Tiredness
  • Swelling
  • Mouth sores
  • Cough
  • Constipation
  • Changes in certain blood tests

Rybrevant may also cause serious side effects, including:1,4

  • Lung problems, with symptoms like shortness of breath, cough, or fever
  • Skin problems, with symptoms like rash, itching, and dry skin
  • Eye problems, with symptoms like eye pain, blurred vision, or changes in vision
  • Infusion-related reactions, with symptoms like fever, nausea, chest discomfort, or lightheadedness

Contact your doctor right away if you have new or worsening symptoms or serious side effects. These are not all the possible side effects of Rybrevant. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with Rybrevant.

Things to know about Rybrevant

Before taking Rybrevant, tell your doctor if you have a history of lung or breathing problems.1,4

Rybrevant can cause skin reactions. Limit sun exposure while taking Rybrevant and for 2 months after treatment is completed. Use a broad-spectrum UVA/UVB sunscreen. Wear protective clothing while in the sun.1,4

Rybrevant can harm an unborn baby. If you can become pregnant, you should use birth control during treatment and for some time after the last dose of Rybrevant. You should also not breastfeed during treatment with Rybrevant and for some time after the last dose. Talk to your doctor about your options for birth control and breastfeeding while taking Rybrevant.1,4

Before beginning treatment for lung cancer, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.

For more information, read the full prescribing information of Rybrevant.

By providing your email address, you are agreeing to our privacy policy. We never sell or share your email address.

More on this topic

Written by: Karen Berger | Last reviewed: May 2021